Figure 7
Figure 7. In vivo differentiation potential of CD45RA subsets. Sublethally irradiated immune-deficient neonates were injected with in vitro–derived or ex vivo–derived indicated cells at concentrations ranging from 0.1 to 1 × 105 cells per mouse. After 4 to 7 weeks, mice were sacrificed and thymi and/or BM cells were analyzed by flow cytometry for shown markers. (A,D) The percentage of donor CD45+ cells in BM and/or thymus from mice injected with CD45RAint derived from OP9-DL4low or OP9-Ctrl cultures (15 and 7 mice, respectively). (B,D) The percentage of CD45+ marker positive cells found in BM and/or thymus of mice injected with CD45RAhi derived from OP9-DL4low or OP9-Ctrl cultures (5 and 4 mice, respectively) or (C-D) ex vivo CD45RAint (7-8 mice).

In vivo differentiation potential of CD45RA subsets. Sublethally irradiated immune-deficient neonates were injected with in vitro–derived or ex vivo–derived indicated cells at concentrations ranging from 0.1 to 1 × 105 cells per mouse. After 4 to 7 weeks, mice were sacrificed and thymi and/or BM cells were analyzed by flow cytometry for shown markers. (A,D) The percentage of donor CD45+ cells in BM and/or thymus from mice injected with CD45RAint derived from OP9-DL4low or OP9-Ctrl cultures (15 and 7 mice, respectively). (B,D) The percentage of CD45+ marker positive cells found in BM and/or thymus of mice injected with CD45RAhi derived from OP9-DL4low or OP9-Ctrl cultures (5 and 4 mice, respectively) or (C-D) ex vivo CD45RAint (7-8 mice).

Close Modal

or Create an Account

Close Modal
Close Modal